Clinica Doctor Balcangiu-Stroescu

Intracavernous injections: when are they indicated and how effective are they?

Intracavernous injections: when are they indicated and how effective are they?
Useful information
April 14, 2026Valentin Iordache

Introduction

Intracavernous injections represent one of the most effective treatment methods for erectile dysfunction, especially in cases where oral therapy does not provide satisfactory results.

Although the idea of an injection may seem intimidating to many patients, this method is safe, well-studied, and widely used in urology.

In many situations, intracavernous injections can restore erectile function even in severe cases.

What are intracavernous injections?

Intracavernous injections involve administering a medication directly into the cavernous bodies of the penis using a very fine needle.

The purpose is:

  • inducing rapid erection
  • increasing local blood flow

Erection occurs independently of sexual stimulation.

How do they work?

Medications used (e.g., alprostadil or vasodilatory combinations):

  • relax smooth muscle
  • dilate blood vessels
  • increase penile blood flow

Result: firm and sustained erection

When are they indicated?

Intracavernous injections are recommended especially in the following situations:

1. Lack of response to oral treatment

  • PDE5 inhibitors (e.g., sildenafil-Viagra) are not effective
  • insufficient or inconsistent effect

2. Severe erectile dysfunction

  • advanced vascular impairment
  • diabetic neuropathy

3. After surgical interventions

  • surgical removal of the prostate (prostatectomy)
  • surgery in the pelvic area

4. Contraindications to oral treatment

  • treatment with nitrates
  • specific cardiovascular conditions

5. Diagnostic (functional testing)

  • evaluation of erectile capacity

How effective are they?

Intracavernous injections have one of the highest success rates:

  • efficacy of approximately 80–90%
  • work even in cases where other treatments fail

How quickly do they act?

  • effect appears in 5–15 minutes
  • duration of erection: 30–60 minutes (depending on dose)

Advantages

very high efficacy
rapid action
do not depend on sexual stimulation
useful in severe cases

Disadvantages

  • requires self-injection
  • possible local discomfort
  • variable psychological acceptability

Are they painful?

In general:

NO or minimally painful

  • the needle is very fine
  • correct technique reduces discomfort

Most patients adapt quickly.

Are there risks?

Like any medical procedure, there are risks, but they are rare if the treatment is performed correctly.

Possible adverse effects:

  • mild local pain
  • bruising
  • prolonged erection (priapism) – rare
  • local fibrosis (with incorrect use)

Risks are reduced through:

  • correct dosing
  • medical instruction
  • monitoring

How to administer correctly?

The patient is instructed by the doctor:

  • choosing the correct injection site
  • using the fine needle
  • respecting the dose

After instruction, the procedure is performed safely.

Are they suitable for long-term use?

✔️ Yes, in certain cases
❗ with periodic monitoring

Many patients use them as an effective long-term solution.

Who are they best suited for?

  • patients with diabetes
  • severe cases
  • lack of response to other therapies

Conclusion

Intracavernous injections are one of the most effective treatment options for erectile dysfunction, especially in complex or treatment-resistant cases.

Although they require adaptation, they provide rapid and safe results in most situations.

When should you consider this option?

  • oral treatment does not work
  • erectile dysfunction is severe
  • there is diabetes or neuropathy

A urological consultation can determine if this method is suitable for you.

If you are struggling with erectile dysfunction and conventional treatments have not produced results, intracavernous injections may be an effective solution.

Schedule a consultation for evaluation and personalized instruction.

Also Read

Related Articles

A single injection for cholesterol — from dreams to first human results
Useful information

A single injection for cholesterol — from dreams to first human results

A Phase 1 trial published in the New England Journal of Medicine (November 2025) brings remarkable results: a single infusion of CTX310, a CRISPR-Cas9 therapy developed by Cleveland Clinic and CRISPR Therapeutics, reduced LDL cholesterol by up to 49% and triglycerides by up to 55% in patients with refractory dyslipidemia — without serious adverse events. The mechanism is unique: instead of blocking a protein or interfering with its mRNA, CTX310 permanently edits the ANGPTL3 gene in hepatic cells, mimicking a natural mutation associated with reduced cardiovascular risk throughout life. The therapy is currently in Phase 1b clinical stage, with updates expected in the second half of 2026. It is not approved and does not replace current treatments. Read the full article for clinical context, comparison with statins and PCSK9 inhibitors, and what these data mean for patients. Medical Disclaimer This article presents results from a Phase 1 clinical trial in an early-stage research phase. The therapy described is not approved and is not available as standard treatment. The information is for educational purposes only. Consult your physician for any medical decision.

June 1, 2026Andra-Elena Balcangiu-Stroescu

Ready to schedule?

Book an appointment online or call us directly.

+40 747 777 107